New Report on AIDS-Related Kaposi’s Sarcoma (ARKS) Therapeutics Market Published by MarketPublishers.com
07 Sep 2011 • by Natalie Aster
LONDON – Kaposi’s sarcoma (KS) is considered an AIDS-defining disease, which means that when HIV-infected patients develop KS, their condition has progressed to AIDS. In the United States, for example, KS serves as an AIDS-defining illness in about 10-15% of HIV-infected homosexual men. With new treatments for AIDS, including antiretroviral therapy (ART), as well as greater awareness of HIV, the number of KS cases due to HIV infection has decreased. Before ART was available, around 90% of patients who had ARKS died from the disease. Today, according to estimates, in areas where antiretroviral therapy (HIV/AIDS treatment) is available, 47% of patients who have ARKS die.
The new research report “AIDS-Related Kaposi’s Sarcoma (ARKS) Therapeutics -Pipeline Assessment and Market Forecasts to 2017” developed by GlobalData provides all-encompassing information and in-depth analysis of the global AIDS-related Kaposi’s sarcoma (ARKS) therapeutics market, focusing on such seven key countries as US, France, Germany, Italy, Spain, UK and Japan. The study features analysis of the current and future competition, offers review of the key industry drivers, restraints and challenges. Above all, valuable insights on the pipeline products within the world ARKS therapeutics market, market revenues data and eight-year forecasts to 2017 are provided as well.
Report Details:
Title: AIDS-Related Kaposi’s Sarcoma (ARKS) Therapeutics -Pipeline Assessment and Market Forecasts to 2017
Published: June, 2011
Pages: 61
Price: US$ 2,000.00
Reports on global therapeutics markets for other diseases are also available:
- Diabetic Nephropathy Therapeutics - Pipeline Assessment and Market Forecasts to 2017
- Premature Ejaculation (PE) Therapeutics - Pipeline Assessment and Market Forecasts to 2017
- Obsessive Compulsive Disorder (OCD) Therapeutics - Pipeline Assessment and Market Forecasts to 2017
- Chronic Myelogenous Leukemia (CML) Therapeutics - Pipeline Assessment and Market Forecasts to 201
- Anxiety Disorders Therapeutics - Pipeline Assessment and Market Forecasts to 2017
- Genital Herpes Therapeutics - Pipeline Assessment and Market Forecasts to 2017
- Choroidal Neovascularization (CNV) Therapeutics - Pipeline Assessment and Market Forecasts to 2017
More new publisher’s market research reports can be found at GlobalData page.
CONTACTS
The Market Publishers, Ltd.
Tanya Rezler
Tel: +44 208 144 6009
Fax: +44 207 900 3970
Analytics & News
